CD274 and Merkel cell skin cancer: The MERKLIN2 trial is a phase II study investigating domatinostat, a histone deacetylase inhibitor, in combination with avelumab in patients with advanced or metastatic MCC who have progressed on anti-PD-L1 therapy (NCT04393753) [106].